Form 4: Vaxcyte Director John Furey Granted Equity Awards

Vaxcyte, Inc. Director John Furey received a grant of 3,041 restricted stock units and 15,372 stock options as part of his compensation.

Summary

• John Furey, a Director of Vaxcyte, Inc. (PCVX), was granted equity awards on June 12, 2025.
• The grant includes 3,041 shares of Common Stock underlying Restricted Stock Units (RSUs). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Additionally, Mr. Furey was granted 15,372 stock options with an exercise price of $34.46 per share.
• The stock options will vest monthly and fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• The stock options have an expiration date of June 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive to neutral. While the grant of equity aligns director interests with shareholders, it is a routine compensation event and does not reflect new operational or financial performance insights for the company.

Positives

• The grant of equity awards to Director John Furey aligns his interests with those of the company's shareholders, incentivizing long-term performance and value creation.

Future Outlook

The equity awards granted to Director John Furey are subject to future vesting conditions, with full vesting anticipated by June 12, 2026, or prior to the next annual meeting of stockholders, contingent on his continuous service.

Industry Context

The grant of restricted stock units and stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to attract, retain, and incentivize talent.

Comparison to Industry Standards

• The structure of equity grants, including RSUs and stock options with vesting schedules tied to continued service, is a standard compensation mechanism widely adopted across publicly traded companies, particularly within the life sciences sector.
• While specific comparable companies or projects are not detailed in this filing, the general approach aligns with typical director compensation frameworks observed in biotech firms of similar market capitalization and development stage.

Related Party Transactions

• The equity grants to Director John Furey represent a standard compensation transaction between the company and a related party (a director), consistent with typical corporate governance practices for incentivizing board members.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value creation, potentially leading to more aligned decision-making.
• Employees: While not directly impacting employees, such compensation practices are part of a broader corporate governance framework that can influence overall company culture and talent retention strategies.

Next Steps

• Continued service of John Furey as a Director of Vaxcyte, Inc.
• Vesting of the 3,041 Restricted Stock Units on or before June 12, 2026.
• Monthly vesting of the 15,372 Stock Options, with full vesting on or before June 12, 2026.

Key Dates

Keywords

Vaxcyte, PCVX, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership